EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyseOpen Access

PARP Inhibitor Maintenance After First-Line Chemotherapy in Advanced-Stage Epithelial Ovarian Cancer

Stamatios Petousis, Ilker Kahramanoglu, Christian Appenzeller-Herzog, Martina A Angeles, Chrysoula Margioula-Siarkou, Joanna Kacperczyk-Bartnik, Esra Bilir, Christos Chatzakis, Giuseppe Caruso, Nicolò Bizzarri, Konstantinos Dinas, David D L Bowtell und 7 weitere

JAMA Network Open · 05.11.2025 · 8 (11) · e2541648

DOI: 10.1001/jamanetworkopen.2025.41648 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift JAMA Network Open, online erschienen am 05.11.2025. Verfasst von Stamatios Petousis und 18 weiteren Autor:innen. Beteiligte Einrichtung: Second Department of Obstetrics and Gynecology, Aristotle University of Thessaloniki, Thessaloniki, Greece. Hauptthemen laut MEDLINE: Poly(ADP-ribose) Polymerase Inhibitors, Carcinoma, Ovarian Epithelial, Ovarian Neoplasms, Maintenance Chemotherapy. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance First-line maintenance therapy with poly(adenosine diphosphate-ribose) polymerase inhibitors (PARP inhibitors) after platinum-based chemotherapy improves progression-free survival (PFS) in advanced epithelial ovarian cancer (EOC), particularly in patients with BRCA -variant or homologous recombination-deficient tumors. However, overall survival (OS) benefits remain uncertain, and toxic effect profiles emphasize the need for optimized patient and agent selection.

Objective

To evaluate the efficacy and safety of first-line PARP inhibitor maintenance therapy compared with chemotherapy alone in advanced-stage EOC, with subgroup analyses by BRCA and HRD status, up-front or interval surgery, chemotherapy response, and residual disease. Data sources Medline, Embase, Web of Science, Cochrane Central Register of Controlled Trials, and ClinicalTrials.gov were searched from database inception to August 19, 2024. Study Selection Randomized clinical trials and prospective 2-arm studies evaluating PARP inhibitor maintenance therapy in patients with advanced-stage EOC responding to first-line platinum-based chemotherapy were included. Data Extraction and Synthesis The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) reporting guideline was followed in reporting this study. Data were independently extracted by 2 reviewers. Random-effects models were used for meta-analysis. Risk of bias was assessed with Cochrane risk of bias and certainty of evidence with the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) framework. Main Outcomes and Measures Primary outcomes were PFS and OS; secondary outcomes included high-grade adverse events.

Results

A total of 7 randomized clinical trials with 4013 patients with advanced-stage epithelial ovarian cancer responding to first-line platinum-based chemotherapy were included. PARP inhibitor maintenance was associated with improved PFS in the overall population (hazard ratio [HR], 0.57; 95% CI, 0.46-0.70; high certainty) and in all molecular subgroups except the homologous recombination proficient group ( BRCA variant: HR, 0.40; 95% CI, 0.35-0.45; BRCA wild type: HR, 0.62; 95% CI, 0.44-0.86; homologous recombination deficient: HR, 0.44; 95% CI, 0.39-0.50; all high certainty). PFS benefits were consistent across surgical timing, chemotherapy responses, and residual disease; for example, surgical timing had HRs of 0.51 (95% CI, 0.31-0.84) for neoadjuvant chemotherapy and 0.54 (95% CI, 0.36-0.81) for primary cytoreductive surgery (all high certainty). No molecular subgroup showed a statistically significant OS improvement (high to low certainty). High-grade adverse events were more common in the PARP inhibitor group (HR, 2.40; 95% CI, 1.16-4.93; high certainty). Observed treatment efficacy and toxic effects varied across PARP inhibitor regimens; for example, the risk ratio for any recurrence or death in the overall study group ranged from 0.53 (95% CI, 0.40-0.70) for senaparib to 0.83 (95% CI, 0.68-1.00) for olaparib, while the risk ratio for high-grade adverse events ranged from 1.15 (95% CI, 0.64-2.06) for veliparib to 4.73 (95% CI, 2.77-8.07) for niraparib. Conclusions and Relevance In this study, no subgroup showed an association between first-line PARP inhibitor maintenance therapy in advanced-stage EOC and improved OS, and findings suggest that the consistency of associated PFS benefits may vary, particularly in homologous recombination proficient and BRCA wild type tumors. Variability in efficacy and toxic effects across subgroups and PARP inhibitor regimens underscores the importance of individualized treatment decisions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Poly(ADP-ribose) Polymerase InhibitorsCarcinoma, Ovarian EpithelialOvarian NeoplasmsMaintenance ChemotherapyHumansFemaleNeoplasm Staging

Substanzen

Poly(ADP-ribose) Polymerase Inhibitors

Autor:innen und Institutionen

  • Second Department of Obstetrics and Gynecology, Aristotle University of Thessaloniki, Thessaloniki, Greece.
  • Department of Gynaecologic Oncology, Biruni University, Istanbul, Turkey.
  • University Medical Library, University of Basel, Basel, Switzerland.
  • Gynaecologic Oncology Unit, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.
  • II Department of Obstetrics and Gynaecology, Medical University of Warsaw, Warsaw, Poland.
  • Department of Obstetrics and Gynaecology, St. Josefs-Hospital Wiesbaden Academic Teaching Hospital of Johannes Gutenberg, University of Mainz, Wiesbaden, Hessen, Germany.

Zitieren

APA

Petousis, S., Kahramanoglu, I., Appenzeller-Herzog, C., Angeles, M. A., Margioula-Siarkou, C., Kacperczyk-Bartnik, J., Bilir, E., Chatzakis, C., Caruso, G., Bizzarri, N., Dinas, K., Bowtell, D. D. L., Garsed, D. W., Ray-Coquard, I., Ledermann, J. A., Friedlander, M., Sotiriadis, A., Heinzelmann-Schwarz, V., & Zwimpfer, T. A. (2025). PARP Inhibitor Maintenance After First-Line Chemotherapy in Advanced-Stage Epithelial Ovarian Cancer. JAMA Network Open, 8(11), e2541648. https://doi.org/10.1001/jamanetworkopen.2025.41648

Vancouver

Petousis S, Kahramanoglu I, Appenzeller-Herzog C, Angeles MA, Margioula-Siarkou C, Kacperczyk-Bartnik J, et al. PARP Inhibitor Maintenance After First-Line Chemotherapy in Advanced-Stage Epithelial Ovarian Cancer. JAMA Network Open. 2025;8(11):e2541648. doi:10.1001/jamanetworkopen.2025.41648

BibTeX
@article{Petousis2025,
  author = {Petousis, Stamatios and Kahramanoglu, Ilker and Appenzeller-Herzog, Christian and Angeles, Martina A and Margioula-Siarkou, Chrysoula and Kacperczyk-Bartnik, Joanna and Bilir, Esra and Chatzakis, Christos and Caruso, Giuseppe and Bizzarri, Nicolò and Dinas, Konstantinos and Bowtell, David D L and Garsed, Dale W and Ray-Coquard, Isabelle and Ledermann, Jonathan A and Friedlander, Michael and Sotiriadis, Alexandros and Heinzelmann-Schwarz, Viola and Zwimpfer, Tibor A},
  title = {PARP Inhibitor Maintenance After First-Line Chemotherapy in Advanced-Stage Epithelial Ovarian Cancer},
  journal = {JAMA Network Open},
  year = {2025},
  volume = {8},
  number = {11},
  pages = {e2541648},
  doi = {10.1001/jamanetworkopen.2025.41648}
}
Kostenlos starten →